 Orchard Therapeutics plc NASDAQ: ORTX has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy MLD, mucopolysaccharidosis type I Hurler syndrome MPS-IH, and Wiskott-Aldrich syndrome WAS. After receiving feedback from the FDA, the company expects to file a marketing application for OTL-200 in pre-symptomatic, early-onset MLD in late 2022 or early 2023. 